Liste des illustrations
Annexe 2 Fiche d’exploitation
Hôpital Ibn Sina, Rabat Fiche N° : 1- Année :
2- Age :
3- Sexe : masculin féminin
4- Antécédents chirurgicaux : opéré non opéré
5- Topographie : Iléale Iléo-colique Colique 6- Traitement : Amino-salicylé Corticoïdes Immunosuppresseurs Anti-TNF
7- Tolérance du jeûne : Bonne tolérance Interruption du jeûne
73
Références
74
[1]. Sobhani, I., et al., Les modifications digestives et nutritionnelles induites par le jeune du ramadan: Exigences methodologiques et pertinence des observations scientifiques. Gastroentérologie clinique et biologique,
1997. 21(11): p. 811-812.
[2]. Azizi, F., Research in Islamic fasting and health. Annals of Saudi medicine, 2002. 22(3/4): p. 186-191.
[3]. Marteau P, A.M., Jian R., Maladie de Crohn. EMC - Traité de Médecine
Akos. 2013: p. 8(2):1-8 [Article 4-0505].
[4]. Morgan, X.C., et al., Dysfunction of the intestinal microbiome in
inflammatory bowel disease and treatment. Genome biology, 2012. 13(9):
p. R79.
[5]. Burcelin, R., S. Nicolas, and V. Blasco-Baque, Microbiotes et maladies
métaboliques-De nouveaux concepts pour de nouvelles stratégies thérapeutiques. médecine/sciences, 2016. 32(11): p. 952-960.
[6]. Gaboriau-Routhiau, V. and N. Cerf-Bensussan, Microbiote intestinal et
développement du système immunitaire. médecine/sciences, 2016. 32(11):
p. 961-967.
[7]. Dutta, A.K. and A. Chacko, Influence of environmental factors on the
onset and course of inflammatory bowel disease. World journal of
gastroenterology, 2016. 22(3): p. 1088.
[8]. Ananthakrishnan, A.N., Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol, 2015. 12(4): p. 205-17.
[9]. Comito, D., A. Cascio, and C. Romano, Microbiota biodiversity in
75
[10]. Molodecky NA, K.G., Environmental risk factors for inflammatory bowel
disease. Gastroenterol Hepatol 2010 ; : p. 6 : 339-46.
[11]. Leone, V., E.B. Chang, and S. Devkota, Diet, microbes, and host
genetics: the perfect storm in inflammatory bowel diseases. Journal of
gastroenterology, 2013. 48(3): p. 315-321.
[12]. Neuman, M.G. and R.M. Nanau, Inflammatory bowel disease: role of diet,
microbiota, life style. Translational Research, 2012. 160(1): p. 29-44.
[13]. Stedman, A., G. Nigro, and P.J. Sansonetti, Le dialogue
microbiote-cellules souches-Un élément clé pour la régénération intestinale.
médecine/sciences, 2016. 32(11): p. 983-990.
[14]. Serban, D.E., Microbiota in inflammatory bowel disease pathogenesis and
therapy: is it all about diet? Nutrition in Clinical Practice, 2015. 30(6): p.
760-779.
[15]. Jess, T., et al., Enteric Salmonella or Campylobacter infections and the
risk of inflammatory bowel disease. Gut, 2011. 60(3): p. 318-324.
[16]. Rodríguez, L.A.G., A. Ruigómez, and J. Panés, Acute gastroenteritis is
followed by an increased risk of inflammatory bowel disease.
Gastroenterology, 2006. 130(6): p. 1588-1594.
[17]. Baumgart, D.C. and W.J. Sandborn, Crohn's disease. Lancet, 2012. 380(9853): p. 1590-605.
[18]. Shaw, S.Y., J.F. Blanchard, and C.N. Bernstein, Association between the
use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. The American journal of gastroenterology, 2011. 106(12): p. 2133.
76
[19]. Husseiny, A.M., et al., The effect of Ramadan fasting on surgical
emergency attendants. Kuwait medical journal, 2008. 40(2): p. 124-126.
[20]. Alami Hassani, R., Approche de la génétique de la Maladie de Crohn,
revue de la littérature. 2018.
[21]. Reif, S., et al., Pre-illness dietary factors in inflammatory bowel disease. Gut, 1997. 40(6): p. 754-760.
[22]. Ekbom, A., et al., Perinatal risk factors for inflammatory bowel disease: a
case-control study. American journal of epidemiology, 1990. 132(6): p.
1111-1119.
[23]. Baron S, Gower C, MerleV, Leplat C, Marti R, Yzet T, et al. Environmental risk factors in inflammatory bowel disease (IBD): a pediatric population-based case-control study. J Pediatr Gastroenterol Nutr 2004;39(Suppl1):S103–4.
[24]. Hugot JP, A., Berrebi D, Bingen E,Cézard JP., Crohn’s disease: the cold
chain hypothesis. . Lancet 2003;: p. 362:2012–5.
[25]. Cézard JP, Hugot JP, Mougenot JF, Navarro J. Maladie de Crohn. In: Navarro J, Schmitz J, editors. Gastroentérologie Pédiatrique, 2e édition. Paris: Flammarion Médecine-Sciences; 2000. p. 354–78.
[26]. Seidman E, LeLeiko N, Ament M, Berman W, Caplan D, Evans J, et al. Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:424–38.
[27]. Zoli, G., et al., Increased energy expenditure in growing adolescents with
Crohn's disease. Digestive diseases and sciences, 1996. 41(9): p.
77
[28]. Varille V, Cézard JP, de Lagausie P, Bellaïche M, Tounian P, Besnard M, etal. Resting energy expenditure before and after surgical resection of gutlesions in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1996;23:13–9.
[29]. Mingrone, G., et al., Elevated diet-induced thermogenesis and lipid
oxidation rate in Crohn disease. The American journal of clinical
nutrition, 1999. 69(2): p. 325-330.
[30]. Motil, K.J., et al., The effect of disease, drug, and diet on whole body
protein metabolism in adolescents with Crohn disease and growth failure.
The Journal of pediatrics, 1982. 101(3): p. 345-351.
[31]. Seidman E, LeLeiko N, Ament M, Berman W, Caplan D, Evans J, et al. Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:424–38.
[32]. Wendland, B.E., et al., Lipid peroxidation and plasma antioxidant
micronutrients in Crohn disease. Am J Clin Nutr, 2001. 74(2): p. 259-64.
[33]. Semeao, E.J., et al., Risk factors for low bone mineral density in children
and young adults with Crohn’s disease. The Journal of pediatrics, 1999.
135(5): p. 593-600.
[34]. Abraham, C. and J.H. Cho, Inflammatory bowel disease. N Engl J Med, 2009. 361(21): p. 2066-78.
[35]. Lee, J.C. and M. Parkes, Genome-wide association studies and Crohn's
78
[36]. Standaert-Vitse, A., et al., Candida albicans colonization and ASCA in
familial Crohn's disease. The American journal of gastroenterology, 2009.
104(7): p. 1745.
[37]. Sendid, B., et al., Glycannes pariétaux de levures et anticorps
spécifiques-Biomarqueurs et outils d’analyse physiopathologique des candidoses et de la maladie de Crohn. médecine/sciences, 2009. 25(5): p. 473-482.
[38]. Standaert–Vitse, A., et al., Candida albicans is an immunogen for anti–
Saccharomyces cerevisiae antibody markers of Crohn’s disease.
Gastroenterology, 2006. 130(6): p. 1764-1775.
[39]. Schuppler M, Loessner MJ. The opportunistic pathogen Listeria monocytogenes: pathogenicity and interaction with the mucosal immune system. Int J Inflam 2010; 2010 : 1-12.
[40]. Sartor, R.B. and S.K. Mazmanian, Intestinal microbes in inflammatory
bowel diseases. The American journal of gastroenterology supplements,
2012. 1(1): p. 15.
[41]. Drouet, M., et al., AIEC colonization and pathogenicity: influence of
previous antibiotic treatment and preexisting inflammation. Inflammatory
bowel diseases, 2012. 18(10): p. 1923-1931.
[42]. Sears, C.L., Enterotoxigenic Bacteroides fragilis: a rogue among
symbiotes. Clinical microbiology reviews, 2009. 22(2): p. 349-369.
[43]. Small, C.-L.N., et al., Persistent infection with Crohn’s disease-associated
adherent-invasive Escherichia coli leads to chronic inflammation and intestinal fibrosis. Nature communications, 2013. 4: p. 1957.
79
[44]. Chassaing, B. and A. Darfeuille–Michaud, The commensal microbiota
and enteropathogens in the pathogenesis of inflammatory bowel diseases.
Gastroenterology, 2011. 140(6): p. 1720-1728. e3.
[45]. Ebalian A., Balian C., 2008. Hépato‐gastro‐entérologie; Ellipses 2008. [46]. Cadiot Guillaume, Galmiche J., Claude Matuchansky, Michel Mignon,
Gastro‐entérologie nouvelle édition.
[47]. Baumgart Daniel C., The diagnosis and treatment of Crohn’s disease and
ulcerative colitis Dtsch Arztebl Int 2009: p. 106(8): 123–33.
[48]. Van Assche, G., et al., The second European evidence-based consensus
on the diagnosis and management of Crohn's disease: definitions and diagnosis. Journal of Crohn's and Colitis, 2010. 4(1): p. 7-27.
[49]. Ebalian A., B.C., Hépato-gastro-entérologie ; ellipses, 2008.
[50]. Frexinos J., B.L., Hépato-gastro-entérologie proctologie 5ème édition. Masson [51]. Tibble, J.A. and I. Bjarnason, Non-invasive investigation of inflammatory
bowel disease. World J Gastroenterol, 2001. 7(4): p. 460-5.
[52]. Bernstein, C.N., M. Fried, and J. Krabshuis, Maladies inflammatoires
chroniques intestinales: une approche globale. World Gastroenterology
Organisation Global Guidelines, 2009: p. 7-8.
[53]. Gendre, J., Place des examens biologiques dans les MICI. Lettre de l’afa n 26, 2006.
[54]. Desreumaux, P., A. Bourreille, and J.-F. Colombel, Physiopathologie des
80
[55]. Dominique, P.-L., Maladie de Crohn mieux comprendre la maladie, son
diagnostic et ses traitements afin d’en optimiser la prise en charge officinale.
Faculté de pharmacie université de Limoges. Année, 2012: p. 14-143.
[56]. Beau, P., et al., Place de l’endoscopie dans le bilan de la maladie de
Crohn. Acta endoscopica, 2004. 34: p. 439-440.
[57]. Horstuis K, e.a., Inflammatory bowel disease diagnosed with US,
MR,scintigraphy, and CT:meta-analysis of prospective studies. radiology,
2008: p. 247(1):64-79.
[58]. EJ., B.D.a.H., Computed tomography-an increasing source of radiation
exposure.N Engl J Med, 2007: p. 3575(22):2277-84.
[59]. Gert Van A, e.a., The second European evidence-based Consensus on the
diagnosis and management of crohn's disease: Definitions and diagnosis.
2010: p. 4(1):7-27.
[60]. Boudiaf, M., P. Soyer, and R. Rymer, Examens morphologiques au cours
des MICI. 2004.
[61]. HAS, H.A.d.S., guide ALD 24 «Maladie de Crohn» [en ligne]. 2008: p. 7-8. [62]. Barthet, M., et al., Imagerie des lésions anopérinéales de la maladie de
Crohn. Gastroentérologie clinique et biologique, 2004. 28(5): p. 52-60.
[63]. Adiot Guillaume, G.J., Claude Matuchansky, Michel and Mignon,
Gastro‐entérologie nouvelle édition.
[64]. Aupetit, A.F.
[65]. Baumgart, D.C., The diagnosis and treatment of Crohn's disease and
81
[66]. Ebalian A., B.C., Hépato‐gastro‐entérologie ; ellipses, 2008.
[67]. Van Kemseke, C., E. Louis, and C. Reenaers, LE MEDICAMENT DU
MOIS. Vedolizumab (Entyvio (R)), nouveau traitement des maladies inflammatoires intestinales. Revue Médicale de Liège, 2015. 70(11): p.
575-82.
[68]. Lamb, Y.N. and S.T. Duggan, Ustekinumab: a review in moderate to
severe Crohn’s disease. Drugs, 2017. 77(10): p. 1105-1114.
[69]. Heuschkel, R.B. and J.A. Walker-Smith, Enteral nutrition in
inflammatory bowel disease of childhood. JPEN, Journal of Parenteral and
Enteral Nutrition, 1999. 23(5): p. S29.
[70]. Goulet O, Serceau F. Maladies inflammatoires du tube digestif. In: Goulet O,Vidailhet M, editors.Alimentation de l’enfant en situations normale et pathologique. Progrès en Pédiatrie 13. Paris: Doin; 2002. p. 267–82 Nouvelle Série.
[71]. Comité de nutritions de la société française de pédiatrie, Prise en charge
nutritionnelle de la maladie de Crohn chez l'enfant et l'adolescent: bases physiopathologiques et mise en pratique. Archives de pédiatrie, 2005.
12(8): p. 1255-1266.
[72]. Pearson, M., et al., Food intolerance and Crohn's disease. Gut, 1993. 34(6): p. 783-787.
[73]. Murch, S.H. and J.A. Walker-Smith, Nutrition in inflammatory bowel
82
[74]. Heuschkel, R.B., et al., Enteral nutrition and corticosteroids in the
treatment of acute Crohn's disease in children. Journal of pediatric
gastroenterology and nutrition, 2000. 31(1): p. 8-15.
[75]. Cosnes J. Alimentations élémentaire, semi-élémentaire, polymérique. Choix, indications, utilisation raisonnée. Rev Prat 1991;41:699–70
[76]. Griffiths, A.M., et al., Meta-analysis of enteral nutrition as a primary
treatment of active Crohn's disease. Gastroenterology, 1995. 108(4): p.
1056-67.
[77]. Greenberg, G.R., et al., Controlled trial of bowel rest and nutritional
support in the management of Crohn's disease. Gut, 1988. 29(10): p.
1309-15.
[78]. Lemar Jerôme, L’appellation « jeûne thérapeutique » est-elle fondée ou
usurpée?, 2011.
[79]. Hakkou, F., et al., L'observance du Ramadan et son retentissement sur la
sécrétion gastrique. Gastroentérologie clinique et biologique, 1994. 18(3):
p. 190-194.
[80]. Iraki, L., et al., Effet du jeûne du Ramadan sur le pH intragastrique
enregistré sur 24 heures chez le sujet sain. Gastroentérologie clinique et
biologique, 1997. 21(11): p. 813-819.
[81]. Kanazawa, M. and S. Fukudo, Effects of fasting therapy on irritable bowel
syndrome. International journal of behavioral medicine, 2006. 13(3): p.
83
[82]. Navarro, S., et al., Comparison of fasting, nasogastric suction and
cimetidine in the treatment of acute pancreatitis. Digestion, 1984. 30(4):
p. 224-230.
[83]. Cheng, A., et al., Involvement of PGC-1α in the formation and
maintenance of neuronal dendritic spines. Nature communications, 2012.
3: p. 1250.
[84]. Donati, A., et al., Effect of aging and anti-aging caloric restriction on the
endocrine regulation of rat liver autophagy. The Journals of Gerontology
Series A: Biological Sciences and Medical Sciences, 2008. 63(6): p. 550-555.
[85]. Wohlgemuth, S.E., et al., Skeletal muscle autophagy and apoptosis during
aging: effects of calorie restriction and life-long exercise. Experimental
gerontology, 2010. 45(2): p. 138-148.
[86]. Hakkou, F., H. Sobhani, and L. Iraki, La survenue de symptômes digestifs
pendant le Ramadan: étude prospective de 1923 sujets. Gastroenterol Clin
Biol, 1991. 15: p. 118-119.
[87]. Iraki, L., et al., Ramadan diet restrictions modify the circadian time
structure in humans. A study on plasma gastrin, insulin, glucose, and calcium and on gastric pH. The Journal of Clinical Endocrinology &
Metabolism, 1997. 82(4): p. 1261-1273.
[88]. Bener, A., et al., Frequency of peptic ulcer disease during and after
Ramadan in a United Arab Emirates hospital. 2006.
[89]. Dönderici, O., et al., Effect of Ramadan on peptic ulcer complications. Scandinavian journal of gastroenterology, 1994. 29(7): p. 603-606.
84
[90]. Özkan, S., et al., Does Ramadan fasting increase acute upper
gastrointestinal haemorrhage? Journal of International Medical Research,
2009. 37(6): p. 1988-1993.
[91]. Emami, M. and H. Rahimi, Effects of Ramadan fasting on acute upper
gastrointestinal bleeding due to peptic ulcer. Journal of Research in
Medical Sciences, 2006. 11(3): p. 170-175.
[92]. Bdioui, F., et al., Maladie ulcéreuse duodénale et Ramadan. La Presse Médicale, 2012. 41(9): p. 807-812.
[93]. Torab, F.C., et al., Perforated peptic ulcer: different ethnic, climatic and
fasting risk factors for morbidity in Al-ain medical district, United Arab Emirates. Asian journal of surgery, 2009. 32(2): p. 95-101.
[94]. Barnich, N., Impact de la nutrition sur l’inflammation intestinale et la
susceptibilité de l’hôte dans un contexte de maladie de Crohn. Nutrition
Clinique et Métabolisme, 2017. 31(3): p. 224.
[95]. Tavakkoli, H., et al., Ramadan fasting and inflammatory bowel disease. Indian J Gastroenterol, 2008. 27(6): p. 239-241.
[96]. Niess, J.H., et al., Review on the influence of stress on immune mediators,
neuropeptides and hormones with relevance for inflammatory bowel disease. Digestion, 2002. 65(3): p. 131-140.
[97]. Afifi, Z., Daily practices, study performance and health during the
Ramadan fast. Journal of the Royal Society of Health, 1997. 117(4): p.
231-235.
85
[99]. arna, S.K., Cyclic motor activity; migrating motor complex: 1985. Gastroenterology, 1985. 89(4): p. 894-913.
[100]. Azizi, F., Research in Islamic fasting and health. Ann Saudi Med, 2002. 22(3-4): p. 186-91.
[101]. Kadri, N., et al., Irritability during the month of Ramadan. Psychosom Med, 2000. 62(2): p. 280-5.